Pinotbio
PrivateLast Round
VC Round
Oct 27, 2025
Est. Valuation
$79.55M
Total Funding Raised
$31.8M
Company Overview
Pinotbio operates in Healthcare & Life Sciences and is based in South Korea. Its latest recorded funding round was a VC Round in October 2025.
Pinotbio is a biotechnology company that develops novel anticancer therapeutics and antibody-drug conjugate (ADC) platform technologies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pinotbio Comparables
Compare Pinotbio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Novelty Nobility Inc. | 88% | |
| Trioar | 85% | |
| IntoCell Inc | 85% |
For institutional investors. Book with your work email.
Pinotbio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Oct 27, 2025 | ||||
| VC Round | Apr 21, 2023 | ||||
| Strategic | Oct 18, 2022 | ||||
| Strategic | Mar 22, 2021 | ||||
| Series C | Nov 9, 2020 | ||||
Series B | Nov 20, 2019 |
For institutional investors. Book with your work email.
Pinotbio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BNH INVESTMENT | VC Round |
| I-ON Asset Management | Series C |
| KB Investment | VC Round, Series B |
| Ulmus Investment | Series C |
| Company K Partners | Series A, Seed |
| Stonebridge Ventures | Series B |
| KB Securities | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 2, 2025
Monthly visitors grew 432% MoM, reaching 1.4K.
- Nov 20, 2019
$8.44M round with participation from Devsisters Ventures and KB Investment.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 15, 2026
On Oct 15th '26, PinotBio, Inc. enters a research collaboration and licensing agreement with Alentis Therapeutics to develop claudin-1-targeting antibody-drug conjugates for oncology indications.
- is_developingOct 14, 2026
PinotBio, Inc. and Alentis Therapeutics enter a research collaboration and licensing agreement to develop next-generation claudin-1-targeting antibody-drug conjugates by combining PinotBio’s PINOT-ADC(R) platform with Alentis’ claudin-1 antibody portfolio on Oct 14th '26.
- licenses_technologyOct 14, 2026
Under the agreement, PinotBio, Inc. grants Alentis an exclusive option to license novel linkers and payloads for use in selected drug development programs.
- is_developingOct 14, 2026
PinotBio, Inc. partners with Alentis Therapeutics under a research collaboration and licensing agreement to develop next-generation cancer ADCs targeting claudin-1, combining its PINOT-ADC(R) platform with Alentis' claudin-1 antibody portfolio to address treatment resistance, improve anti-cancer activity, and reduce side effects.
For institutional investors. Book with your work email.
Pinotbio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Pinotbio's valuation, stock price, and market status.
Is Pinotbio a public or private company?
Pinotbio is a private company.
What is the current stock price of Pinotbio?
Pinotbio is a private company, so its shares have no public market price. Caplight tracks Pinotbio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Pinotbio worth (valuation)?
Pinotbio's valuation is estimated at $79.5M based on funding round data.
Can I buy Pinotbio stock?
Pinotbio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Pinotbio's last funding round?
Pinotbio's most recent funding round was VC Round on October 27, 2025.
Who are the main investors in Pinotbio?
Key investors in Pinotbio include IMM Investment.
Will Pinotbio IPO soon?
No public IPO plans have been announced for Pinotbio.
How can I track Pinotbio secondary market activity?
Caplight tracks bids, offers, and trades in Pinotbio's shares on secondary markets.